Literature DB >> 11166323

(S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord.

N K Thomas1, R A Wright, P A Howson, A E Kingston, D D Schoepp, D E Jane.   

Abstract

(S)-3,4-Dicarboxyphenylglycine (DCPG) has been tested on cloned human mGlu1-8 receptors individually expressed in AV12-664 cells co-expressing a rat glutamate/aspartate transporter and shown to be a potent and selective mGlu8a receptor agonist (EC(50) value 31+/-2 nM, n=3) with weaker effects on the other cloned mGlu receptors (EC(50) or IC(50) values >3.5 microM on mGlu1-7). Electrophysiological characterisation on the neonatal rat spinal cord preparation revealed that (S)-3,4-DCPG depressed the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) giving a biphasic concentration-response curve showing EC(50) values of 1.3+/-0.2 microM (n=17) and 391+/-81 microM (n=17) for the higher and lower affinity components, respectively. The receptor mediating the high-affinity component was antagonised by 200 microM (S)-alpha-methyl-2-amino-4-phosphonobutyrate (MAP4, K(D) value 5.4+/-1.5 microM (n=3)), a group III metabotropic glutamate (mGlu) receptor antagonist. The alpha-methyl substituted analogue of (S)-3,4-DCPG, (RS)-3,4-MDCPG (100 microM), antagonised the effects of (S)-3,4-DCPG (K(D) value 5.0+/-0.4 microM, n=3) in a similar manner to MAP4. (S)-3,4-DCPG-induced depressions of the fDR-VRP in the low-affinity range of the concentration-response curve were potentiated by 200 microM (S)-alpha-ethylglutamate (EGLU), a group II mGlu receptor antagonist, and were relatively unaffected by MAP4 (200 microM). However, depressions of the fDR-VRP mediated by the AMPA selective antagonist (R)-3,4-DCPG were not potentiated by EGLU, suggesting that the low-affinity component of the concentration-response curve for (S)-3,4-DCPG is not due to antagonism of postsynaptic AMPA receptors. It is suggested that the receptor responsible for mediating the high-affinity component is mGlu8. The receptor responsible for mediating the low-affinity effect of (S)-3,4-DCPG has yet to be identified but it is unlikely to be one of the known mGlu receptors present on primary afferent terminals or an ionotropic glutamate receptor of the AMPA or NMDA subtype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166323     DOI: 10.1016/s0028-3908(00)00169-6

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  32 in total

Review 1.  Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Authors:  James N C Kew; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-25       Impact factor: 4.530

2.  Group III mGluR7 and mGluR8 in the amygdala differentially modulate nocifensive and affective pain behaviors.

Authors:  Enza Palazzo; Yu Fu; Guangchen Ji; Sabatino Maione; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2008-05-16       Impact factor: 5.250

Review 3.  Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.

Authors:  Marion S Mercier; David Lodge
Journal:  Neurochem Res       Date:  2014-08-22       Impact factor: 3.996

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Modulation of short-term plasticity in the corticothalamic circuit by group III metabotropic glutamate receptors.

Authors:  Christine L Kyuyoung; John R Huguenard
Journal:  J Neurosci       Date:  2014-01-08       Impact factor: 6.167

Review 6.  Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

Authors:  Shen Yin; Colleen M Niswender
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

7.  Acute pharmacological modulation of mGluR8 reduces measures of anxiety.

Authors:  Robert M Duvoisin; Tim Pfankuch; Julie M Wilson; Julie Grabell; Vijay Chhajlani; Dean G Brown; Edwin Johnson; Jacob Raber
Journal:  Behav Brain Res       Date:  2010-04-10       Impact factor: 3.332

Review 8.  Metabotropic glutamate receptors: physiology, pharmacology, and disease.

Authors:  Colleen M Niswender; P Jeffrey Conn
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

Review 9.  Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.

Authors:  Susan Duty
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

10.  Metabotropic glutamate receptors mGluR4 and mGluR8 regulate transmission in the lateral olfactory tract-piriform cortex synapse.

Authors:  Paulianda J Jones; Zixiu Xiang; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2008-06-29       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.